Great Lakes Advisors LLC Has $1.67 Million Position in Lantheus Holdings, Inc. $LNTH

Great Lakes Advisors LLC decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 23.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,535 shares of the medical equipment provider’s stock after selling 9,934 shares during the quarter. Great Lakes Advisors LLC’s holdings in Lantheus were worth $1,669,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Pilgrim Partners Asia Pte Ltd acquired a new position in Lantheus in the third quarter worth about $59,000. Sector Gamma AS grew its stake in shares of Lantheus by 28.0% in the 3rd quarter. Sector Gamma AS now owns 64,403 shares of the medical equipment provider’s stock valued at $3,303,000 after purchasing an additional 14,102 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Lantheus in the 3rd quarter worth approximately $3,866,000. UNIVEST FINANCIAL Corp lifted its position in shares of Lantheus by 46.0% during the 3rd quarter. UNIVEST FINANCIAL Corp now owns 31,024 shares of the medical equipment provider’s stock worth $1,591,000 after buying an additional 9,781 shares during the period. Finally, Covestor Ltd boosted its stake in Lantheus by 430.5% in the 3rd quarter. Covestor Ltd now owns 1,740 shares of the medical equipment provider’s stock valued at $90,000 after buying an additional 1,412 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent analyst reports. Truist Financial increased their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Mizuho increased their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 0.4%

Shares of NASDAQ LNTH opened at $66.92 on Friday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The firm’s 50-day simple moving average is $64.87 and its 200 day simple moving average is $59.88. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.44 billion, a price-to-earnings ratio of 28.12 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. During the same period in the previous year, the firm posted $1.70 earnings per share. The company’s revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.